Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB34714 in post-herpetic neuralgia
2004-000975-32Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brivaracetam in postherpetic neuralgia (PHN) (3 arms), sponsored by UCB. Primary endpoints: Primary efficacy of UCB34714 200 mg/day vs placebo and Primary efficacy of UCB34714 400 mg/day vs placebo. Started Sep 2004; status: completed.
02
Drugs
brivaracetam
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2004-000975-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000975-32.